Virtual Library
Start Your Search
M. Ezzdin
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-066 - Bevacizumab Combined with Docetaxel : A Real Active Second Line Regimen in Elderly Patients with Advanced Non-Small Cell Cancer (NSCLC) (ID 1285)
09:30 - 09:30 | Author(s): M. Ezzdin
- Abstract
Background:
Majority of patients with non-small cell lung cancer (NSCLC) are elderly, and age is known to be an important factor for management and treatment. Elderly are underpresented in cancer research. Therefore, we conducted this phase II study aiming at assessing the efficacy and safety of adding bevacizumab to docetaxel as a second line treatment of elderly patients with advanced non squamous NSCLC
Methods:
Twenty five previously treated elderly patients with advanced non squamous NSCLC (stage III, IV) were enrolled into this study between May 2011 and May 2014. All patients received docetaxel 60 mg/m[2] followed by bevacizumab 15mg/kg, both agents were given via I.V infusion on day 1 and the cycle was repeated every 21 days until disease progression or unacceptable toxicity developed.
Results:
The median age was 70 years old (range 65-79 years); 19 (76%) patients were men; ECOC PS was 0 in 6 (24%) patients, 1 in 12 (48%) patients and 2 in 7 (28%) patients. The objective response rate was 60%, while disease control rate was 84%.The median progression-free survival time was 7 months, while the median overall survival time was 19.8 months. Grade 3/4 neutropenia had been recorded in 18(72%) patients, and grade 3/4 fatigue had occurred in 5(20%) patients. No cases of severe bleeding nor treatment-related deaths had been reported in this study.
Conclusion:
Bevacizumab added to docetaxel showed a real activity as a second line treatment in previously treated elderly patients with advanced NSCLC and has an acceptable toxicity.
